APS injection relieves knee pain in osteoarthritis

Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Intra-articular injection of autologous protein solution (APS) is safe and effective for the treatment of knee osteoarthritis (OA).

Why this matters

  • There has been an interest in injection treatments for OA to stave off the need for metal resurfacing.

Key results 

  • Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain scores were similar between groups at all time points until 12 mo, when the APS group had significantly higher scores (P=.02).
  • From baseline, both groups improved over time at 12 mo with WOMAC pain score (APS, P<.0001 control p=".0012).</li">
  • No significant differences between groups in visual analog scale (P=.05); difference observed at 12 mo (P=.06)
  • MRI data showed size increase from baseline in osteophytes (P=.032) and bone marrow lesions (P=.041) in control patients, whereas APS patients showed no changes.
  • No differences in adverse events between groups. 

Study design 

  • Randomized controlled trial of APS in 46 unilateral patients with knee OA.
  • Researchers recorded patient-reported outcomes and adverse events from 2 wk through 12 mo follow-up.
  • Funding: Biomet Zimmer. 

Limitations

  • Small sample size.